{"filing":{"accession_number":"0001213900-26-099576","cik":"0001860657","ticker":"ALLR","company_name":"Allarity Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-11","primary_document":"ea0305408-8k_allarity.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026099576/ea0305408-8k_allarity.htm"},"events":[{"id":33215,"run_id":30535,"accession_number":"0001213900-26-099576","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Allarity announced that its newly formed subsidiary, Allarity Acquisition Corp. (a SPAC), has filed a Registration Statement on Form S-1 for a proposed $100–$115 million initial public offering. This is a material capital allocation and strategic business event—the creation and public offering of a subsidiary SPAC—that would affect a reasonable investor's assessment of the company's capital structure and strategic direction. While the SPAC itself is a separate entity, Allarity's sponsorship (via ALLR Sponsor LLC owning ~25% post-offering) and the diversion of management resources constitute a material operational and strategic disclosure. This does not fit neatly into the specific categories (not M\u0026A activity, not a debt issuance, not a dilutive equity issuance by Allarity itself), so operational_other is the most appropriate classification.","company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36600,"accession_number":"0001213900-26-099576","item_number":"8.01","item_title":"Other Matters.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Allarity announced that its newly formed subsidiary, Allarity Acquisition Corp. (a SPAC), has filed a Registration Statement on Form S-1 for a proposed $100–$115 million initial public offering. This is a material capital allocation and strategic business event—the creation and public offering of a subsidiary SPAC—that would affect a reasonable investor's assessment of the company's capital structure and strategic direction. While the SPAC itself is a separate entity, Allarity's sponsorship (via ALLR Sponsor LLC owning ~25% post-offering) and the diversion of management resources constitute a material operational and strategic disclosure. This does not fit neatly into the specific categories (not M\u0026A activity, not a debt issuance, not a dilutive equity issuance by Allarity itself), so operational_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T16:15:48.362151+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36600,"accession_number":"0001213900-26-099576","item_number":"8.01","item_title":"Other Matters.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Allarity announced that its newly formed subsidiary, Allarity Acquisition Corp. (a SPAC), has filed a Registration Statement on Form S-1 for a proposed $100–$115 million initial public offering. This is a material capital allocation and strategic business event—the creation and public offering of a subsidiary SPAC—that would affect a reasonable investor's assessment of the company's capital structure and strategic direction. While the SPAC itself is a separate entity, Allarity's sponsorship (via ALLR Sponsor LLC owning ~25% post-offering) and the diversion of management resources constitute a material operational and strategic disclosure. This does not fit neatly into the specific categories (not M\u0026A activity, not a debt issuance, not a dilutive equity issuance by Allarity itself), so operational_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T16:15:48.362151+00:00","company_name":"Allarity Therapeutics, Inc.","ticker":"ALLR","filing_date":"2026-09-14"}]}